Kenya launched a new product, MedipristTM (Mifepristone),
geared towards safe motherhood, with the primary aim
of reducing maternal mortality caused by unsafe
Statistics in Kenya show that unsafe abortion accounts for
approximately 35 per cent of maternal deaths.
launch saw 100 healthcare providers - gynaecologists, medical
officers, clinical officers, pharmacists and pharmaceutical
technologists- from Mombasa, Kilifi and Kwale counties, come
together at Sarova Whitesands Beach Resort and Spa to engage in
discussions around prevention of maternal mortality and unsafe
event’s Guest Speaker, Reproductive Health Network Chairperson
Dr. John Nyamu walked the participants through the current
revision of the Standards and Guidelines for reduction of
Panelists, Consultant Obs/ Gyn and member of KOGS Dr. Mutua
Chamia, Obs/Gyn- Ministry of Health CPGH Dr. Soita Musimbi,
Consultant Obs/ Gyn and member of KOGS Dr. Marjan S. Ramadhan,
Provincial Reproductive Health Officer CPGH Dr. Jennifer Othigo
and Consultant Obs/ Gyn and member of KOGS Dr. David Kapanga,
shared practices and experiences of preventing unsafe abortion
in Kenya with the participants.
arrival of Mediprist in the market is a game changer for
providers who wish to prevent unsafe abortion, with a
medication solution that is as safe as surgical procedure
for their patients.
registered product, Mediprist is mifepristone, and meets all
the quality requirements.
is available to order at Marie Stopes Kenya, with full
training and technical support for providers and their
patients.” said Dr Jesse Njunguru, MSK Program Pharmacist
and Marie Stopes Kenya staff took place.